Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

Desmond Padhi, Graham Jang, Brian Stouch, +2

Journal of Bone and Mineral Research

SclerostinHealthy SubjectsImmunologyPharmacotherapySclerostin Monoclonal Antibody +16

Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans

Narender R. Gavva, James Treanor, András Garami, +18

Pain

InflammationMolecular PharmacologyTrpv1 BlockadeSelective Trpv1 AntagonistHyperthermia +13

Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease

Edmund C. Lee, Tania Valencia, Charles Allerson, +22

Nature Communications

Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study

Desmond Padhi, Mark Allison, Alan Kivitz, +4

The Journal of Clinical Pharmacology

SclerostinImmunologyPharmacotherapySclerostin Antibody RomosozumabSerum Type 1 +15

Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours

Leonid Gibiansky, Liviawati Sutjandra, Sameer Doshi, +6

Clinical Pharmacokinetics

OncologyMetronomic TherapyPharmacologySolid TumoursPopulation Pharmacokinetic Analysis +4

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies

Hong Li, Tae Hyung Han, Naomi Hunder, +2

The Journal of Clinical Pharmacology

Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes

Graham Jang, Steven Wrighton, Leslie Z. Benet

Biochemical Pharmacology

BiochemistryLiver PhysiologyRu 486Molecular BiologyHepatotoxicity +9

Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase

Nuria Tamayo, Lillian Liao, Martin H. Goldberg, +11

Bioorganic & Medicinal Chemistry Letters

Medicinal ChemistryP38 Map KinaseBiochemistryNatural SciencesMedicine +7

An Extended Terminal Half-Life for Darbepoetin Alfa

Desmond Padhi, Liyun Ni, Blaire Cooke, +2

Clinical Pharmacokinetics

Lifespan ExtensionMedicineSecondary MetabolitePharmacotherapyPharmacology +2

Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role

Balaji Agoram, Ken Aoki, Sameer Doshi, +5

Journal of Pharmaceutical Sciences

InflammationAltered ReceptorSignal TransductionErythropoiesis-stimulating ProteinsPhysiology +10